301 related articles for article (PubMed ID: 26080399)
1. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis.
Eisinger-Mathason TS; Mucaj V; Biju KM; Nakazawa MS; Gohil M; Cash TP; Yoon SS; Skuli N; Park KM; Gerecht S; Simon MC
Proc Natl Acad Sci U S A; 2015 Jun; 112(26):E3402-11. PubMed ID: 26080399
[TBL] [Abstract][Full Text] [Related]
2. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways.
Kelleher FC; O'Sullivan H
Oncotarget; 2016 Jul; 7(27):42792-42804. PubMed ID: 27074562
[TBL] [Abstract][Full Text] [Related]
5. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response.
Shao D; Zhai P; Del Re DP; Sciarretta S; Yabuta N; Nojima H; Lim DS; Pan D; Sadoshima J
Nat Commun; 2014; 5():3315. PubMed ID: 24525530
[TBL] [Abstract][Full Text] [Related]
6. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
7. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
8. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
[TBL] [Abstract][Full Text] [Related]
9. [YAP induces chromosomal instability in liver cancer patients].
Weiler S
Pathologe; 2018 Dec; 39(Suppl 2):185-188. PubMed ID: 30206654
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
11. YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Ye S; Lawlor MA; Rivera-Reyes A; Egolf S; Chor S; Pak K; Ciotti GE; Lee AC; Marino GE; Shah J; Niedzwicki D; Weber K; Park PMC; Alam MZ; Grazioli A; Haldar M; Xu M; Perry JA; Qi J; Eisinger-Mathason TSK
Cancer Res; 2018 May; 78(10):2705-2720. PubMed ID: 29490948
[TBL] [Abstract][Full Text] [Related]
12. EP300 promotes lung cancer cell proliferation by regulating the oncogenic transcription of Hippo-YAP signaling pathway.
Li S; Shi J; Wang L; Zhang D; Zhang H
Biochem Biophys Res Commun; 2024 Jan; 692():149330. PubMed ID: 38048728
[TBL] [Abstract][Full Text] [Related]
13. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
14. Regulation of YAP by mechanical strain through Jnk and Hippo signaling.
Codelia VA; Sun G; Irvine KD
Curr Biol; 2014 Sep; 24(17):2012-7. PubMed ID: 25127217
[TBL] [Abstract][Full Text] [Related]
15. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.
Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P
World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598
[TBL] [Abstract][Full Text] [Related]
17. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
18. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
[TBL] [Abstract][Full Text] [Related]
19. YAP and the Hippo pathway in cholangiocarcinoma.
Sugihara T; Isomoto H; Gores G; Smoot R
J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
[TBL] [Abstract][Full Text] [Related]
20. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression.
He C; Mao D; Hua G; Lv X; Chen X; Angeletti PC; Dong J; Remmenga SW; Rodabaugh KJ; Zhou J; Lambert PF; Yang P; Davis JS; Wang C
EMBO Mol Med; 2015 Nov; 7(11):1426-49. PubMed ID: 26417066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
